Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biomarin Pharmaceutical

62.03
-0.6800-1.08%
Post-market: 62.030.00000.00%19:45 EDT
Volume:2.24M
Turnover:138.75M
Market Cap:11.89B
PE:28.10
High:65.40
Open:64.26
Low:60.92
Close:62.71
Loading ...

Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term

Zacks
·
28 Feb

Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus

Zacks
·
28 Feb

Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA

Zacks
·
26 Feb

Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Simply Wall St.
·
26 Feb

BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA

PR Newswire
·
25 Feb

Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect

StockStory
·
25 Feb

What To Expect From United Therapeutics’s (UTHR) Q4 Earnings

StockStory
·
25 Feb

Stifel Nicolaus Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
25 Feb

Biomarin Announces Appointment of Timothy P. Walbert to Board of Directors

THOMSON REUTERS
·
25 Feb

BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors

PR Newswire
·
25 Feb

BioMarin (BMRN) is an Incredible Growth Stock: 3 Reasons Why

Zacks
·
25 Feb

BUZZ-U.S. STOCKS ON THE MOVE-BioMarin, Azul, Sun Communities

Reuters
·
24 Feb

Oppenheimer upgrades BioMarin on long term outlook

Investing.com
·
24 Feb

Does BioMarin (BMRN) Have the Potential to Rally 40.54% as Wall Street Analysts Expect?

Zacks
·
24 Feb

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Zacks
·
24 Feb

BUZZ-BioMarin rises after Oppenheimer upgrades on revenue growth prospects

Reuters
·
24 Feb

BioMarin Pharmaceutical Raised to Outperform From Perform by Oppenheimer

Dow Jones
·
24 Feb

Oppenheimer Upgrades BioMarin Pharmaceutical to Outperform From Market Perform, Price Target is $98

MT Newswires Live
·
24 Feb

Biomarin Pharmaceutical : Oppenheimer Raises to Outperform From Perform

THOMSON REUTERS
·
24 Feb

BioMarin price target raised to $80 from $78 at Scotiabank

TipRanks
·
21 Feb